Posted by Michael Wonder on 19 Jan 2023
Abbott receives FDA approval for Navitor, a next generation TAVI system designed to treat aortic stenosis
17 January 2023 - Abbott's new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant.
Abbott today announced that the US FDA has approved the company's latest-generation transcatheter aortic valve implantation system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery.
